Around the world, scientists and doctors are working on various means to combat the coronavirus. In Russia, for example,
One of them, a variation of the Sputnik V vaccine, is even planned to be tested. At least the Russian pharmaceutical company Generium has submitted an application for a clinical trial of the drug.
Based on the development of the Gamaleya Institute, we made an intranasal form of the vaccine, which is simply injected into the nose.
Daniil TalanskyGeneral Director General
According to the expert, such a vaccine is better tolerated and at the same time not inferior to it in terms of effectiveness. The developers hope that the drug will be registered in about six months.
Recall that back in August it became known about the completion of preclinical testing of the nasal form of "Sputnik V". The price of clinical trials of the vaccine was then estimated at 400 million rubles.